The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)

Biochemical and Biophysical Research Communications

Volumn 404, Issue 4, 2011, Pages 958-962

  Xing, Joanna ^a   Liu, Ruixin ^a   Xing, Mingzhao ^a   Trink, Barry ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF inhibitor; BRAF mutation; Genetic dependent therapy; PLX4032; RG7204; Thyroid cancer

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLX 4032; RAS PROTEIN; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL MUTANT; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; MITOSIS INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER; WILD TYPE; AMINO ACID SUBSTITUTION; DRUG EFFECT; DRUG RESISTANCE; GENETICS; THYROID TUMOR; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; THYROID NEOPLASMS;

EID: 79151475164     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.088     Document Type: Article

References (18)

1. S.F. Altekruse, C.L. Kosary, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, J. Ruhl, N. Howlader, Z. Tatalovich, H. Cho, A. Mariotto, M.P. Eisner, D.R. Lewis, K. Cronin, H.S. Chen, E.J. Feuer, D.G. Stinchcomb, B.K. Edwards (Eds.), SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, based on November 2009 SEER data submission, posted to the SEER web site, 2010. http://seer.cancer.gov/csr/1975_2007/.
2. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83:2638-2648.
3. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 2005, 12:245-262.
4. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 2007, 742-762.
5. Tang K.T., Lee C.H. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J. Chin. Med. Assoc. 2010, 73:113-128.
6. Li H.F., Chen Y., Rao S.S., Chen X.M., Liu H.C., Qin J.H., Tang W.F., Yue-Wang, Zhou X., Lu T. Recent advances in the research and development of B-Raf inhibitors. Curr. Med. Chem. 2010, 17:1618-1634.
7. Smalley K.S. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr. Opin. Invest. Drugs 2010, 11:699-706.
8. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105:3041-3046.
9. Joseph E.W., Pratilas C.A., Poulikakos P.I., Tadi M., Wang W., Taylor B.S., Halilovic E., Persaud Y., Xing F., Viale A., Tsai J., Chapman P.B., Bollag G., Solit D.B., Rosen N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 2010, 107:14903-14908.
10. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
11. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E.A., Wong B., Tsang G., West B.L., Powell B., Shellooe R., Marimuthu A., Nguyen H., Zhang K.Y., Artis D.R., Schlessinger J., Su F., Higgins B., Iyer R., D'Andrea K., Koehler A., Stumm M., Lin P.S., Lee R.J., Grippo J., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., Chapman P.B., Flaherty K.T., Xu X., Nathanson K.L., Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467(7315):596-599.
12. Welkos S., O'Brien A. Determination of median lethal and infectious doses in animal model systems. Methods Enzymol. 1994, 235:29-39.
13. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464(7287):427-430.
14. Casado E., De Castro J., Belda-Iniesta C., Cejas P., Feliu J., Sereno M., González-Barón M. Molecular markers in colorectal cancer: genetic bases for a customised treatment. Clin. Transl. Oncol. 2007, 9:549-554.
15. Chang D.Z., Kumar V., Ma Y., Li K., Kopetz S. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J. Hematol. Oncol. 2009, 2:18.
16. Heist R.S., Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 2009, 10:59-68.
17. Xing M. Genetic-targeted therapy of thyroid cancer: a real promise. Thyroid 2009, 19:805-809.
18. Salerno P., De Falco V., Tamburrino A., Nappi T.C., Vecchio G., Schweppe R.E., Bollag G., Santoro M., Salvatore G. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2010, 95:450-455.